These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
806 related articles for article (PubMed ID: 19464103)
1. Anti-proliferative activity of heat shock protein (Hsp) 90 inhibitors via beta-catenin/TCF7L2 pathway in adult T cell leukemia cells. Kurashina R; Ohyashiki JH; Kobayashi C; Hamamura R; Zhang Y; Hirano T; Ohyashiki K Cancer Lett; 2009 Oct; 284(1):62-70. PubMed ID: 19464103 [TBL] [Abstract][Full Text] [Related]
2. Efficacy of Hsp90 inhibition for induction of apoptosis and inhibition of growth in cervical carcinoma cells in vitro and in vivo. Schwock J; Pham NA; Cao MP; Hedley DW Cancer Chemother Pharmacol; 2008 Apr; 61(4):669-81. PubMed ID: 17579866 [TBL] [Abstract][Full Text] [Related]
3. The heat-shock protein 90 inhibitor, geldanamycin, induces apoptotic cell death in Epstein-Barr virus-positive NK/T-cell lymphoma by Akt down-regulation. Jeon YK; Park CH; Kim KY; Li YC; Kim J; Kim YA; Paik JH; Park BK; Kim CW; Kim YN J Pathol; 2007 Oct; 213(2):170-9. PubMed ID: 17768706 [TBL] [Abstract][Full Text] [Related]
4. 17-AAG and 17-DMAG-induced inhibition of cell proliferation through B-Raf downregulation in WT B-Raf-expressing uveal melanoma cell lines. Babchia N; Calipel A; Mouriaux F; Faussat AM; Mascarelli F Invest Ophthalmol Vis Sci; 2008 Jun; 49(6):2348-56. PubMed ID: 18281615 [TBL] [Abstract][Full Text] [Related]
5. Distinct regulation of insulin receptor substrate-1 and -2 by 90-kDa heat-shock protein in adrenal chromaffin cells. Yoshikawa N; Nemoto T; Satoh S; Maruta T; Yanagita T; Chosa E; Wada A Neurochem Int; 2010 Jan; 56(1):42-50. PubMed ID: 19737590 [TBL] [Abstract][Full Text] [Related]
7. The heat shock protein 90 inhibitor 17-AAG induces cell cycle arrest and apoptosis in mantle cell lymphoma cell lines by depleting cyclin D1, Akt, Bid and activating caspase 9. Georgakis GV; Li Y; Younes A Br J Haematol; 2006 Oct; 135(1):68-71. PubMed ID: 16925576 [TBL] [Abstract][Full Text] [Related]
8. Heat shock protein 90 inhibition is cytotoxic to primary AML cells expressing mutant FLT3 and results in altered downstream signalling. Al Shaer L; Walsby E; Gilkes A; Tonks A; Walsh V; Mills K; Burnett A; Rowntree C Br J Haematol; 2008 May; 141(4):483-93. PubMed ID: 18373709 [TBL] [Abstract][Full Text] [Related]
9. Multiple kinase pathways involved in the different de novo sensitivity of pancreatic cancer cell lines to 17-AAG. Liu H; Zhang T; Chen R; McConkey DJ; Ward JF; Curley SA J Surg Res; 2012 Jul; 176(1):147-53. PubMed ID: 22099584 [TBL] [Abstract][Full Text] [Related]
10. The Hsp90 inhibitor 17-allylamide-17-demethoxygeldanamycin induces apoptosis and differentiation of Kasumi-1 harboring the Asn822Lys KIT mutation and down-regulates KIT protein level. Yu W; Rao Q; Wang M; Tian Z; Lin D; Liu X; Wang J Leuk Res; 2006 May; 30(5):575-82. PubMed ID: 16213582 [TBL] [Abstract][Full Text] [Related]
11. [Study on signal transduction pathway in differentiation and apoptosis of leukemia cells induced by heat shock protein inhibitor]. Yu WJ; Rao Q; Wang M; Tian Z; Xu ZF; Wang JX Zhonghua Xue Ye Xue Za Zhi; 2007 Oct; 28(10):677-80. PubMed ID: 18399173 [TBL] [Abstract][Full Text] [Related]
12. Proteome-wide changes induced by the Hsp90 inhibitor, geldanamycin in anaplastic large cell lymphoma cells. Schumacher JA; Crockett DK; Elenitoba-Johnson KS; Lim MS Proteomics; 2007 Aug; 7(15):2603-16. PubMed ID: 17610208 [TBL] [Abstract][Full Text] [Related]
13. Effects of Hsp90 inhibition in neuroblastoma: analysis of drug sensitivity, target modulation and the influence of bone marrow microenvironment. Jayanthan A; Fowler J; Hawkins L; Lamers F; Teja B; Incoronato A; Anderson R; Narendran A J Exp Ther Oncol; 2008; 7(3):183-93. PubMed ID: 19066127 [TBL] [Abstract][Full Text] [Related]
14. Coadministration of the heat shock protein 90 antagonist 17-allylamino- 17-demethoxygeldanamycin with suberoylanilide hydroxamic acid or sodium butyrate synergistically induces apoptosis in human leukemia cells. Rahmani M; Yu C; Dai Y; Reese E; Ahmed W; Dent P; Grant S Cancer Res; 2003 Dec; 63(23):8420-7. PubMed ID: 14679005 [TBL] [Abstract][Full Text] [Related]
15. Development of 17-allylamino-17-demethoxygeldanamycin hydroquinone hydrochloride (IPI-504), an anti-cancer agent directed against Hsp90. Sydor JR; Normant E; Pien CS; Porter JR; Ge J; Grenier L; Pak RH; Ali JA; Dembski MS; Hudak J; Patterson J; Penders C; Pink M; Read MA; Sang J; Woodward C; Zhang Y; Grayzel DS; Wright J; Barrett JA; Palombella VJ; Adams J; Tong JK Proc Natl Acad Sci U S A; 2006 Nov; 103(46):17408-13. PubMed ID: 17090671 [TBL] [Abstract][Full Text] [Related]
16. Potent cytotoxic C-11 modified geldanamycin analogues. Tian ZQ; Wang Z; MacMillan KS; Zhou Y; Carreras CW; Mueller T; Myles DC; Liu Y J Med Chem; 2009 May; 52(10):3265-73. PubMed ID: 19405528 [TBL] [Abstract][Full Text] [Related]
17. Gene expression profiling of human colon cancer cells following inhibition of signal transduction by 17-allylamino-17-demethoxygeldanamycin, an inhibitor of the hsp90 molecular chaperone. Clarke PA; Hostein I; Banerji U; Stefano FD; Maloney A; Walton M; Judson I; Workman P Oncogene; 2000 Aug; 19(36):4125-33. PubMed ID: 10962573 [TBL] [Abstract][Full Text] [Related]
18. Heat shock protein 90 inhibitor induces apoptosis and attenuates activation of hepatic stellate cells. Myung SJ; Yoon JH; Kim BH; Lee JH; Jung EU; Lee HS J Pharmacol Exp Ther; 2009 Jul; 330(1):276-82. PubMed ID: 19329756 [TBL] [Abstract][Full Text] [Related]
19. The heat-shock protein 90 inhibitor 17-allylamino-17-demethoxygeldanamycin suppresses glial inflammatory responses and ameliorates experimental autoimmune encephalomyelitis. Dello Russo C; Polak PE; Mercado PR; Spagnolo A; Sharp A; Murphy P; Kamal A; Burrows FJ; Fritz LC; Feinstein DL J Neurochem; 2006 Dec; 99(5):1351-62. PubMed ID: 17064348 [TBL] [Abstract][Full Text] [Related]
20. Combination mammalian target of rapamycin inhibitor rapamycin and HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin has synergistic activity in multiple myeloma. Francis LK; Alsayed Y; Leleu X; Jia X; Singha UK; Anderson J; Timm M; Ngo H; Lu G; Huston A; Ehrlich LA; Dimmock E; Lentzsch S; Hideshima T; Roodman GD; Anderson KC; Ghobrial IM Clin Cancer Res; 2006 Nov; 12(22):6826-35. PubMed ID: 17121904 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]